BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31706717)

  • 1. Feasibility of extended chemoradiotherapy plus surgery for patients with cT4b esophageal carcinoma.
    Anderegg MCJ; Ruurda JP; Gisbertz SS; Blom RLGM; Sosef MN; Wijnhoven BPL; Hulshof MCCM; Bergman JJGHM; van Laarhoven HWM; van Berge Henegouwen MI
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):626-631. PubMed ID: 31706717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
    Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy.
    Kumagai K; Mariosa D; Tsai JA; Nilsson M; Ye W; Lundell L; Rouvelas I
    Dis Esophagus; 2016 Oct; 29(7):734-739. PubMed ID: 26316181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.
    Chen Y; Lu Y; Wang Y; Yang H; Xia Y; Chen M; Song H; Li T; Li D; Wang J; Li S; Wang J
    Dis Esophagus; 2014; 27(2):134-40. PubMed ID: 23088212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
    Bosch DJ; Muijs CT; Mul VE; Beukema JC; Hospers GA; Burgerhof JG; Plukker JT
    Ann Surg Oncol; 2014 Feb; 21(2):605-11. PubMed ID: 24100962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
    Pucher PH; Rahman SA; Walker RC; Grace BL; Bateman A; Iveson T; Jackson A; Rees C; Byrne JP; Kelly JJ; Noble F; Underwood TJ
    Eur J Surg Oncol; 2020 Dec; 46(12):2248-2256. PubMed ID: 32694054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
    Chang KJ; Reid T; Senzer N; Swisher S; Pinto H; Hanna N; Chak A; Soetikno R
    Gastrointest Endosc; 2012 Jun; 75(6):1139-46.e2. PubMed ID: 22520270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
    Koëter M; van der Sangen MJ; Hurkmans CW; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
    Radiat Oncol; 2015 Mar; 10():59. PubMed ID: 25884226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Unresectable T4b Esophageal Cancer: Practice Patterns and Outcomes From the National Cancer Data Base.
    Cushman TR; Shaaban SG; Moreno AC; Lin C; Verma V
    Am J Clin Oncol; 2019 Feb; 42(2):154-159. PubMed ID: 30499838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
    Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC
    Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer: choice of new approach.
    Suzuki G; Yamazaki H; Aibe N; Masui K; Sasaki N; Shimizu D; Kimoto T; Shiozaki A; Dohi O; Fujiwara H; Ishikawa T; Konishi H; Naito Y; Otsuji E; Yamada K
    Radiat Oncol; 2018 Dec; 13(1):246. PubMed ID: 30547811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?
    Markar S; Gronnier C; Duhamel A; Pasquer A; Théreaux J; du Rieu MC; Lefevre JH; Turner K; Luc G; Mariette C
    J Clin Oncol; 2015 Nov; 33(33):3866-73. PubMed ID: 26195702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.
    Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
    Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
    Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemoradiotherapy followed by surgery in treatment of locally advanced esophageal carcinoma: a phase II trial].
    Fu JH; Rong TH; Li XD; Hu Y; Ou W; Hu YH; Li Q
    Ai Zheng; 2004 Nov; 23(11 Suppl):1473-6. PubMed ID: 15566661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.